Between 15 and 18 August, six separate NHS digital contracts, procurements and strategies were reported. Not one of them came with a price.
That is not a criticism of any individual trust. It is a description of how a multi-billion pound technology market reports itself, and it is a problem for anyone trying to sell into it, invest in it or scrutinise it.
What Was Actually Announced
The list, as compiled in Nelson Advisors’ UK HealthTech Pulse for those four days, is substantial.
University Hospitals of Leicester NHS Trust won a five-year national contract to deliver digital structured education for adults with diabetes across England, extending its MyDESMOND platform, built with the University of Leicester’s Leicester Diabetes Centre and Promatica Digital, to cover Type 1 diabetes for the first time. No financial figure disclosed.
Leeds and York Partnership NHS Foundation Trust is preparing an electronic patient record tender while running ambient voice technology pilots. No value specified.
Lewisham and Greenwich NHS Trust is progressing an EPR procurement toward a 2027 go-live, alongside ambient voice and patient-facing technology. No figure disclosed.
Calderdale and Huddersfield NHS Foundation Trust confirmed a 1 September go-live for an EPR-embedded clinical decision support tool using the Anticholinergic Medication Index, flagging anticholinergic burden in patients aged 65 and over. No cost given.
Gloucestershire Health and Care NHS Foundation Trust published a digital strategy running to 2031. No budget specified. Central London Community Healthcare was confirmed as integrator for population health across four North West London boroughs. No financial details.
The Only Number in the Period
One item carried a figure, and it came from outside the NHS.
Innovate UK’s Women in Innovation awards, announced on 7 August, gave 61 founders £75,000 each, including healthtech companies working on AI for MRI, home diagnostics and wearables. That is £4.6 million in total, spread across 61 recipients.
Set that against a national five-year contract covering diabetes education for all of England, whose value is unknown. The grant programme is smaller by any plausible measure, and it is the only part of the picture a reader can actually size.
Grant funding gets published because the funder’s purpose is partly to demonstrate the money went out. Procurement values get published inconsistently, and the difference is about incentives rather than importance.
Why the Opacity Matters Commercially
A supplier deciding whether to build a product for the NHS needs to know roughly what such contracts are worth.
This is not a complaint about secrecy. Individual trusts have legitimate reasons not to lead with a number: commercial confidentiality during a live procurement, values that depend on volumes not yet known, and contracts whose worth is a range rather than a figure. A five-year national agreement priced per participant genuinely does not have a single headline value on the day it is signed.
But the aggregate effect of many defensible individual decisions is a market that cannot see itself. That is worth separating from any judgement about the parties making them, because the fix is not for any single trust to behave differently.
Without that, the sales case rests on anecdote and on whatever the last comparable deal was rumoured to be. Pricing becomes guesswork, and the firms best placed to guess are the incumbents who have won before, which is a structural advantage that has nothing to do with product quality.
For investors the problem is sharper. Sizing a market requires transaction values, and a sector whose deals are announced without them is one where the addressable market has to be estimated from headcount, population or bed numbers instead. Those proxies are weak, and they are part of why the mid-market funding gap for scaling UK digital health companies is a recurring complaint.
The values are frequently obtainable later, through contract award notices and freedom of information requests. But “available to someone who files a request” and “visible to the market” are different states, and only one of them shapes decisions at the moment they are made.
The Electronic Patient Record Pattern
Two of the six items are EPR procurements, which is the largest single category of NHS technology spending and the one where opacity costs most.
An EPR is the core clinical system of a hospital. Buying one is a multi-year commitment that shapes every other piece of software a trust can use, and switching later is close to prohibitive. These are among the largest technology decisions any public body makes.
Both trusts here are pairing the EPR work with ambient voice technology, which is the current adjacent purchase: tools that transcribe and structure clinical conversations. That pairing is worth watching, because a technology bought alongside a core system tends to end up bundled with it, and bundling is where a competitive market quietly narrows.
The same logic applies to any wholesale infrastructure market where one supplier arrives first: the early relationships set the defaults, and the defaults outlast the procurement.
What Four Days Implies About a Year
Six items across four days is a rate, and it is worth doing the arithmetic even though the answer comes with heavy caveats.
At one and a half items a working day, and roughly 250 working days in a year, the implied run rate is somewhere near 375 reported NHS digital contracts, procurements and strategies annually. Spread across the couple of hundred trusts in England, that is most organisations doing something visible most years.
The caveats matter and should be stated plainly. This is one newsletter’s selection rather than an exhaustive register, so it captures what an industry publication judged worth reporting, not everything that happened. Four days is a tiny sample. August is an atypical month, with summer recess and holiday cover cutting across normal announcement patterns. And the six items are not comparable units: a five-year national contract and a published strategy document are very different things to count together.
What survives all of that is the shape rather than the number. This is not a market where a handful of large deals land each year and everyone in the sector knows about each one. It is a market with continuous, distributed, locally-decided activity, and that changes what opacity costs.
If there were twenty deals a year, a supplier could track each one individually and price from a known comparator set. At several hundred, spread across independent buyers making their own decisions, no supplier can hold the picture in their head. The information would have to be aggregated to be usable, and aggregation is exactly what the missing values prevent.
That is the practical case for publishing contract values at the point of announcement rather than months later in a notice nobody reads. Not transparency as a principle, but as the input a competitive market needs to function at this volume.
What the Deals Have in Common
Reading the six together, a theme emerges that is more interesting than any single item.
Every one is about information rather than treatment. Structured education delivered digitally, patient records, transcription, medication risk flagging, population health integration, a digital strategy. None of them is a drug, a scanner or a building.
That is a real shift in what the NHS buys, and it favours a different kind of supplier. The Calderdale item is a good illustration: an index that flags anticholinergic burden in older patients is not new clinical knowledge, it is existing knowledge embedded at the point where a prescribing decision is made. The value is in the placement, not the science.
Software companies are good at placement. That is the market opening up here, and it is why the absence of price signals is more than a transparency complaint. It is a barrier to the competition that would make the spending work harder, in much the same way that shifting health responsibilities onto employers only produces better outcomes if the people carrying the new duty can see what good looks like.
About The Author
More Stories
Planning Officers Are 2,660 Short and the Gap Is Widening
Whitbread Is Cutting 3,800 Jobs to Add 3,600 Hotel Rooms
Gilt Yields Hit an Eighteen-Year High and Japan Broke 3%